US20230181479A1 - Polymer based formulation for release of drugs and bioactives at specific git sites - Google Patents
Polymer based formulation for release of drugs and bioactives at specific git sites Download PDFInfo
- Publication number
- US20230181479A1 US20230181479A1 US18/164,174 US202318164174A US2023181479A1 US 20230181479 A1 US20230181479 A1 US 20230181479A1 US 202318164174 A US202318164174 A US 202318164174A US 2023181479 A1 US2023181479 A1 US 2023181479A1
- Authority
- US
- United States
- Prior art keywords
- drug
- release
- capsule
- pharmaceutical composition
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000003814 drug Substances 0.000 title claims abstract description 103
- 229940079593 drug Drugs 0.000 title claims abstract description 100
- 229920000642 polymer Polymers 0.000 title claims abstract description 42
- 230000000975 bioactive effect Effects 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title abstract description 31
- 238000009472 formulation Methods 0.000 title abstract description 20
- 210000001072 colon Anatomy 0.000 claims abstract description 26
- 239000002775 capsule Substances 0.000 claims description 81
- 239000002552 dosage form Substances 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 27
- 150000002500 ions Chemical class 0.000 claims description 20
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 15
- 235000010413 sodium alginate Nutrition 0.000 claims description 15
- 239000000661 sodium alginate Substances 0.000 claims description 15
- 229940005550 sodium alginate Drugs 0.000 claims description 15
- 238000000576 coating method Methods 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000011248 coating agent Substances 0.000 claims description 10
- 229920005615 natural polymer Polymers 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 230000008569 process Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 7
- 229920001059 synthetic polymer Polymers 0.000 claims description 7
- 239000007963 capsule composition Substances 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 239000007931 coated granule Substances 0.000 claims 1
- 238000013266 extended drug release Methods 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 238000013269 sustained drug release Methods 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 abstract description 10
- 210000000936 intestine Anatomy 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 235000010443 alginic acid Nutrition 0.000 description 33
- 229920000615 alginic acid Polymers 0.000 description 33
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 32
- 229940072056 alginate Drugs 0.000 description 32
- 150000001768 cations Chemical class 0.000 description 17
- 238000004090 dissolution Methods 0.000 description 15
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 13
- 238000012377 drug delivery Methods 0.000 description 11
- 239000007909 solid dosage form Substances 0.000 description 10
- 230000003111 delayed effect Effects 0.000 description 9
- 239000000499 gel Substances 0.000 description 9
- 229960004963 mesalazine Drugs 0.000 description 8
- 239000008363 phosphate buffer Substances 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 6
- 239000002702 enteric coating Substances 0.000 description 6
- 238000009505 enteric coating Methods 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 230000000541 pulsatile effect Effects 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- 230000002378 acidificating effect Effects 0.000 description 5
- 239000008186 active pharmaceutical agent Substances 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 229960000381 omeprazole Drugs 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 4
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- 230000027288 circadian rhythm Effects 0.000 description 4
- 238000004132 cross linking Methods 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 230000036571 hydration Effects 0.000 description 4
- 238000006703 hydration reaction Methods 0.000 description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 4
- 210000002429 large intestine Anatomy 0.000 description 4
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin hydrochloride Natural products CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 229920003134 Eudragit® polymer Polymers 0.000 description 3
- -1 Fe+++ ions Chemical class 0.000 description 3
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 3
- 241000736262 Microbiota Species 0.000 description 3
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000003628 erosive effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- 229960001300 metoprolol tartrate Drugs 0.000 description 3
- 229960005019 pantoprazole Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229910001369 Brass Inorganic materials 0.000 description 2
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 241000792859 Enema Species 0.000 description 2
- 229920003139 Eudragit® L 100 Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000010951 brass Substances 0.000 description 2
- 229960004436 budesonide Drugs 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 229920006184 cellulose methylcellulose Polymers 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000000112 colonic effect Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000000599 controlled substance Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000007920 enema Substances 0.000 description 2
- 229940079360 enema for constipation Drugs 0.000 description 2
- 229960004770 esomeprazole Drugs 0.000 description 2
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 2
- 238000013265 extended release Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229960000598 infliximab Drugs 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 2
- 229940126409 proton pump inhibitor Drugs 0.000 description 2
- 239000000612 proton pump inhibitor Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- UKBBZNRSHOCRNP-UHFFFAOYSA-N 1-[4-(2-methoxyethyl)phenoxy]-3-(propan-2-ylamino)propan-2-ol;hydrochloride Chemical compound Cl.COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 UKBBZNRSHOCRNP-UHFFFAOYSA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000004881 Amebiasis Diseases 0.000 description 1
- 206010001980 Amoebiasis Diseases 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 244000106483 Anogeissus latifolia Species 0.000 description 1
- 235000011514 Anogeissus latifolia Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710121765 Endo-1,4-beta-xylanase Proteins 0.000 description 1
- 229920003141 Eudragit® S 100 Polymers 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000001922 Gum ghatti Substances 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- 208000016988 Hemorrhagic Stroke Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 102000004459 Nitroreductase Human genes 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 108010059820 Polygalacturonase Proteins 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 1
- 108010083204 Proton Pumps Proteins 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 240000004584 Tamarindus indica Species 0.000 description 1
- 235000004298 Tamarindus indica Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 108010084650 alpha-N-arabinofuranosidase Proteins 0.000 description 1
- 229960000528 amlodipine Drugs 0.000 description 1
- HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 229940127088 antihypertensive drug Drugs 0.000 description 1
- 229940020544 apriso Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 150000003851 azoles Chemical class 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002778 chronopharmacological effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013267 controlled drug release Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940113965 delzicol Drugs 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 210000004921 distal colon Anatomy 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108010093305 exopolygalacturonase Proteins 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000013022 formulation composition Substances 0.000 description 1
- 108010066429 galactomannanase Proteins 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 235000019314 gum ghatti Nutrition 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 229940013926 lialda Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229960003105 metformin Drugs 0.000 description 1
- 229960002237 metoprolol Drugs 0.000 description 1
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 108020001162 nitroreductase Proteins 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940072223 pentasa Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920002959 polymer blend Polymers 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 1
- 229960004157 rabeprazole Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention provides desired drug/bio-active release formulation in solid dosage form comprising variable physico-chemical properties of Active Pharmaceutical Ingredients (APIs) and other bio-actives including proteins by means of polymer capsule as a unit dosage form.
- the above said dosage form comprises natural polymer example, sodium alginate with bi- and/or trivalent ions chemically balanced cations to control the release of drug/bio-actives at specific time and at specific GIT sites.
- Solid dosage forms and such drug delivery systems with oral route remains the most desired and accepted route of administration. Oral dosage systems are able to release the drug at a constant rate for a given time period with multiple release profile/s are thus of interest.
- Conventional solid dosage forms consist of active agent and biologically inert auxiliary substances which are the pharmaceutical excipients.
- Conventional dosage forms release the drug following which drug is very rapidly dissolved and quickly builds up to a maximum high concentration in GIT. The result is an undulating concentration of the drug in the stomach or intestine, thus in the systemic circulation and tissues.
- the dosage form may thus release high of or low concentrations of drugs which may under-serve the patient's needs. Often, this may cause problems in maintaining therapeutic drug levels over only brief duration of time which may either lead to an insufficient efficacy provoking an excessive drug dumping.
- an ideal drug delivery system should be (a) able to deliver the drug at a rate to co-relate in vivo bioequivalence, and (b) deliver the drug to its targeted site, for example, as in the case of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and colonic cancer.
- IBD inflammatory bowel disease
- IBS irritable bowel syndrome
- colonic cancer for example, as in the case of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and colonic cancer.
- IBD inflammatory bowel disease
- IBS irritable bowel syndrome
- CDDS controlled drug delivery systems
- the dosage form has uniform packing characteristics over a range of different particle size distributions and is capable of processing into various solid dosage forms viz. tablets, capsules, pellets, enteric coating, etc.
- rate of drug release is controlled by the rate of water penetration into the dosage form matrix.
- various rate controlling polymers are added into the dosage form. This increases the process and thus the cost of the therapy.
- the drug dumping is associated especially with such unit dosage forms.
- various specialized technologies such as, osmotic controlled release formulations require number of processing operations which subsequently increases the processing time.
- Multiple processing of unit dosage form includes coating with specific polymers, e.g. enteric coating (Time controlled drug delivery systems, In: A. T. Florence, J. Siepmann (Eds.) Modern Pharmaceutics Volume 2: Applications and Advances, Informa Healthcare USA; Inc., New York, N.Y.; 2009; 1-22).
- Newer solid dosage forms are envisioned to achieve the drug and other actives to be released at various GIT sites.
- all solid dosage forms overrides the physiological implications, including the gastric pH, varied gastric retention times and other physiological limitations including the organ emptying time.
- many drugs e.g. Omeprazole, esomeprazole, pantoprazole, etc.
- process technology now routinely practiced as a ‘pelletization process’ followed by enteric coating using pH sensitive polymers (example, Eudragit).
- Chronopharmaceutics provides drug release that ideally matches the circadian rhythm (24 hour) of the body in association with a specific disease, e.g. hypertension (U.S. Pat. No. 6,229,396).
- Pulsatile drug delivery systems have gained increasing interest during recent years because of its ability to release the drug rapidly and completely after a defined lag time.
- Pulsatile release profiles are suitable for drugs with (1) higher first-pass metabolism, (2) which develop biological tolerance, (3) which are targeted to a specific site in GIT, such as colon, (4) which need protection from degradation, and to meet the chronotherapeutical diseases.
- Ambulatory blood pressure has reported to exhibit diurnal pattern with a surge in the early morning time which is considered to be a major factor behind high risk of cardiac death, ischemic and hemorrhagic stroke. Therefore, there is a need of an antihypertensive drug to have higher plasma concentration for morning surge in blood pressure 9,10,11 .
- various formulation strategies to target the colon include the polymeric coatings of the dosage form to provide the delayed drug release because of the degradation of coating facilitated by presence of either change in pH, pressure, time-dependent polymeric films or microorganism flora.
- Colon targeted drug delivery system need to overcome the hurdles in the form of acidic pH of stomach and slightly alkaline pH in small intestine. They are expected to initiate drug release in large intestine. These systems work on the principle of solubilization of polymer coating at alkaline pH above 7. Polymers such as Eudragit L100 which is soluble above pH 5.5 to 6.5 and Eudragit 5100, soluble above pH 7 are commonly used.
- enzymes such as glucoronidase, xylosidase, arabinosidase, amylase, pectinase, xylanase, galactomannanase, nitroreductase, azoreductase, deaminase, urea dehydroxylase have been reported to produce micro-biota of colon.
- Polysaccharides of natural origin obtained from plant, algal, animal or microbial origin such as calcium pectinate, chitosan, chondroitin sulphate, galactomanan, and amylose are mostly used for micro-biota-activated coatings.
- Pressure-dependent devices are meant to be ruptured because of the relatively elevated pressure in large intestine compared to small intestine due to peristaltic movement.
- time-dependent coatings releases the pay load in colon as a consequence of either of the following mechanisms, which are, timed erosion, disintegration or enhanced permeability irrespective of above mentioned physiological variables. It has been hypothesized that, there is a marked decrease in the pH of proximal large intestine of IBD patients. This could be the cause in few of the instances, that coating of Eudragit S100 has failed to dissolve as intact tablet. On the other hand, as revealed by scintigraphic evaluation, tablets coated with Eudragit L100, were found to dissolve in the distal small intestine (Eur. J. Pharm. Sci., 2013, 49, 712-722; Int. J. Pharm, 2013, 457, 372-395).
- U.S. Pat. No. 6,228,396 discloses a colonic drug delivery composition comprising a starch capsule containing drug. Colon targeting is achieved by means of a coating comprising of a pH sensitive material, a redox sensitive material or a material which could be broken down by the enzymes or microbiota present in the colon.
- Capsule formulations containing API mesalamine for colon targeting is available in market (e.g. Delzicol, Apriso, Pentasa).
- tablet formulations coated with a pH dependent coating which dissolves above pH 7 are also available in market (e.g. Asacol HD, Lialda).
- modified release formulations containing ionisable drugs and/or ionic polymers such as enteric coating can be affected by pH and composition on intestinal fluids ( Journal of Pharmacy and Pharmacology; 2014; 1-10).
- U.S. Pat. Nos. 5,171,580, 5,603,9975, WO2011045775, WO 2005030173 and U.S. Pat. No. 4,871,549 disclose coated drugs maximizing the use of excipients in the formulation leading to increase in the number of manufacturing processes.
- the technologies involve tableting process and the use of coating of solid dosage forms with different polymers.
- the pharmaceutical process involves multi-steps and use of multiple excipients.
- the ‘tunability’ to achieve the control over the drug release profiles is questionable with often drug dumping and lower patient compliance.
- Applicants propose a non-tableting, non-coating platform (capsule as a solid dosage form) using natural polymer/s to control the release of drug/bioactives at specific time and at various specific GIT sites.
- the rate of release of actives is achieved as immediate-, extended-, sustained, lag-, pulsatile-, or delayed-drug release profiles (e.g. site—colon delivery).
- capsules as a dosage form comprising sodium alginate with bi- and/or trivalent chemically balanced ions to control the release of drug/bio-actives at specific time and at specific GIT sites are demonstrated.
- the present invention provides solid dosage formulation in the form of capsule to achieve multiple drug dissolution profiles.
- the dosage form protects degradation of the drug in gastric environment (APIs e.g. Omeprazole, esomeprazole, pantoprazole and all grouped azoles), or achieve controlled/extended release of drug/bio-actives, and attain lag or pulse release profile (e.g. Metoprolol, Amlodipine, etc.).
- the dosage form also achieves the delayed release in small or large intestine or at colon site (e.g. Mesalamine, budesonide, infliximab, peptides, proteins or other bioactives etc.).
- the preparation of such solid dosage formulation is also provided.
- the invention also encompasses that such modified drug dissolution platform is useful to supplement the nutraceuticals or dietary minerals with divalent cations (e.g. Na + , Mg ++ , Ca ++ ).
- the present invention relates to a drug delivery formulation in the form of polymer capsules for delivering different drugs and bioactives at various GIT sites, inclduing stomach, intestine and colon having varied drug release profiles.
- the capsule of the present invention achieves the delayed release of the anti-inflammatory or anticacner drugs, e.g. mesalamine, 5-flurouracil, etc. for colon delivery.
- the anti-inflammatory or anticacner drugs e.g. mesalamine, 5-flurouracil, etc. for colon delivery.
- the formulation composition reported in the present invention does not involve application of coating step by using any of the available enteric or biodegradable polymers nor any other excipient.
- the present invention comprises the dosage form using polymer of natural origin, sodium alginate which is resistant to acidic pH.
- the thickness and toughness of the polymer/s is so adjusted that, it remains intact during its transit through stomach and intestine. Once the capsule reaches colon, it will achieve the burst release of the drug because of the swelling of polymer at higher pH values and also by subsequent rapid erosion.
- the release profiles achieved are highly essential in treating Crohn's disease, colon cancer, Irritable Bowl Syndrome (IBS) and other GI-related disorders.
- One aspect of the invention is to design the capsules using alginate crossed linked with multi-cations in the form of Form-Fill-Seal (FFS) process for site-specific delivery as colon targeting.
- FFS Form-Fill-Seal
- FIG. 1 Schematic for preparation of capsule dosage form comprising polymer and ions and the Dimensions of drug releasing polymer capsule using multi ions of alginate gel.
- FIG. 2 Varied release profiles of APIs with alginate and/or bi- or trivalent ions and/or polymers.
- FIG. 3 Dissolution profile of H + proton pump inhibitor Omeprazole—a pH unstable API.
- FIG. 4 Dissolution profile of Metformin Hydrochloride showing Immediate Release (IR) Profile.
- FIG. 5 Dissolution profile of Metoprolol tartrate in 0.1M HCl (4 Hrs), pH 6.8 Phosphate buffer (4 Hrs) and pH 7.6 Phosphate buffer (4 Hrs).
- FIG. 6 Dissolution profile of Mesalamine in 0.1M HCl (2 Hrs), pH 6.0 Phosphate buffer (1 Hr) and pH 7.2 Phosphate buffer (3 Hrs).
- the present invention is related to a polymer-based formulation for release of drugs and bio-actives at GIT specific sites.
- the invention describes a dosage form comprising sodium alginate with bi- and/or trivalent chemically balanced cations to control the release of drug/bio-actives at specific time and at specific GIT sites.
- the applicant details a modified drug releasing pharmaceutical formulation as a capsule dosage form comprising Form-Fill-Seal (FFS) capsule processing. This brings ease of administration, subsequently avoiding inconvenient route of administration for dosage forms like suppositories and enemas. Avoidance of systemic absorption of drugs and consequently its unwanted distribution to tissues in the body is also achieved.
- FFS Form-Fill-Seal
- the polymeric capsule can deliver drugs or proteins and peptide drugs. Rectal administration is also limited by availability of lesser number of dosage forms (solutions, foams, enemas, and suppositories) and drug also remains localized to rectum and distal colon if administered by this route.
- the invention describes the preparation of said formulation and its release profile for wide-ranging therapeutics as a “capsule” prepared by finely tuned composition of bi- and/or trivalent cations and natural and/or synthetic polymer/s or combination thereof to control the release of drug/bioactives at specific time and at specific GIT sites.
- modified release includes, but is not limited to, immediate-, extended-, sustained-, lag- and pulsatile-, or delayed-, or combination of drug release profiles in pharmaceutical formulation.
- the present invention demonstrates a novel composition that offers greater multiplicity and flexibility in the release profile to be obtained with finely tuned natural polymer, sodium alginate using di- and/or tri-valent cations and natural/semi-synthetic/synthetic polymer.
- alginate gels are dependent mainly upon and affinity towards bi-valent or trivalent cations which bring about (a) stiffness of the individual polymer chains in alginate and (b) the nature and the strength of the forces whereby bi- or trivalent metal ions bind different chains together.
- alginate gels are crosslinked with bi- or trivalent cations.
- the release rate profiles of bioactives is achieved when the alginate concentration was varied from 1% to 6% w/v ionic concentrations. For example, when alginate concentration was higher than 2%, it promoted the saturation for ionic binding. Also, addition of Fe +++ promoted faster diffusion of Ca ++ and reduced Ca ++ equilibrium concentration. Also, Fe +++ ions entrapped in the alginate capsule promoted greater absorption of water compared to pure alginate gel.
- the alginate achieves lower gelation almost 4 times than the equivalent amount of CaCl 2 and/or FeCl 3 .
- the formulation of the present invention allows the release of drug/bioactive to reach at specific time and at specific site/s in a controlled manner e. g. extended-, sustained-, lag-, pulsatile-, or delayed-drug release profiles.
- the formulation is modulated by process of forming capsule shell to achieve desired release profile/s.
- the type and content of natural polymer blended and/or cross-linked with bi- and/or trivalent ions in the form of their salts with one or many natural or synthetic excipients/polymers to reach appropriate thickness of the layer on substrate was considered.
- capsule shell composition provide a high unit dose of the active ingredient; exhibit desired in-vitro release profiles and in-vivo performance.
- the formulation of the invention presents the advantage that it is cost effective since one polymer with bare API is needed to control the release of the active ingredient, thus facilitating relatively cheaper manufacturing process.
- the formulation of the invention presents an advantage of compatibility between natural polymer and drug/bioactive with better stability on storage.
- Capsule shell composition comprises sodium alginate, bi- and/or trivalent cations in the form of their salts, for example: CaCl 2 , FeCl 3 , BaCl 2 , MgCl 2 , and MnCl 2 and/or polymers, for example: CMC, HPMC, HPC, starch, cross-linked sodium CMC/HPC; high-molecular weight polyvinylalcohols; gums such as natural gum, psyllium husk, tamarind gum, agar, agarose, sodium alginate, carrageenan, gum arabic, gum ghatti, gum karaya, gum tragacanth and xanthan gum; hydrophilic colloids such as alginates, carbopol and polyacrylamides; other substances such as arbinogalactan, pectin, amylopectin, gelatin, and N-vinyl lactams; polysaccharides; chitosan, hyaluronic acid
- the dosage form of the present invention is a capsule comprising (a) drug/bioactives including peptide, proteins, natural/mineral oils, enzymes, vitamins and mixtures thereof; (b) polymer sodium alginate blended with natural or synthetic polymers.
- the polymer blends that can be used with cross-linked alginate includes but not limited to HPMC, CMC, PVA, gelatin, starch and so on.
- the present invention comprises pharmaceutical composition of capsule shell comprising:
- the pharmaceutical composition of the present invention comprise a therapeutically effective quantity of drug/bioactive or its pharmaceutically acceptable salts.
- the said composition is in a solid unit dosage form, as a capsule, made up of a single polymer of natural origin, which can be tuned to achieve various drug release profiles, such as, immediate (e. g. metformin capsule, FIG. 4 ), pulsatile (e.g. metoprolol hydrochloride capsule, FIG. 5 ) and colon targeted or delayed release (e. g. mesalamine capsule, FIG. 6 ).
- the pharmaceutical composition of the present invention provides protection from acidic environment in the stomach for proton pump inhibitor drugs without the need to apply enteric coating; these drugs include but not limited to Omeprazole, Rabeprazole, Pantoprazole and so on, which act by immediate drug release as soon as the dosage form reaches proximal part of small intestine.
- the pharmaceutical composition of the present invention can deliver site specific drug release to colon for various APIs (e. g. mesalamine, budesonide, infliximab, etc.) as well as proteins and peptides, etc.
- the pharmaceutical composition of the present invention can also be prepared using any of the substrates such as stainless-steel capsule pins, glass rods, teflon rods and brass capsule pins.
- the pharmaceutical composition of the present invention which is a capsule formulation can be altered by achieving suitable thickness and toughness so as to deliver drug to the colonic region.
- the required thickness and toughness of the composition is achieved by increasing the number of capsule layers which may vary from one to eight.
- the drug release can be modified or defined by the number of layers of the substrate. As the number of alginate layers increases, the release rate of bioactive from the capsule decreases.
- composition of the invention is delivered via systemic route when the drug/bioactive is a protein or a peptide.
- the pharmaceutical composition of the invention is useful for delivering the drug/bioactive at specific site and specific time in conditions such as IBD and cancer.
- the bioactive release rate can be tuned by changing the number of layers of capsules.
- the rate of hydration in stomach until its emptying time will be negligible. This will preserve the release of bioactive. Further, due to high ions the capsule will have lower hydration in intestinal buffers. The capsule at intestinal pH and due to long retention time there will initiate hydration resulting in swelling. While, it reaches to colon, the swelled capsule is expected to release the bioactive in colon pH. This can be tuned based on number of alginate layers and crosslinking ratio's of ions.
- the formulation of the invention delivers the bioactives by oral route when the drug/bioactive is protein or a peptide. It is expected that the capsule will protect these bioactives from early release in stomach and intestine. The rate of release will be delayed when the capsule reaches colon.
- Suitable grade of alginate polymer was selected and a gel was prepared in distilled water in concentration ranging from 0.1-6% w/v.
- a substrate e.g. stainless-steel capsule pins, glass rods, teflon rods and brass capsule pins
- the substrate on which polymer gel was coated was dipped into aqueous solution of di- or trivalent ions or their mixtures (example, CaCl 2 , FeCl 3 and MgCl 2 having concentration from 0.025 to 12% w/v) thereof in the form of their salts and/or polymer having concentration from 0.05 to 6% w/v and 0.01 to 6% w/v respectively for a time period between 30 seconds to 1 hour ( FIG. 1 ).
- This process allows cross-linking which leads to solidification of alginate.
- the substrate was then removed and dried in hot air oven at any temperature between 40° C. to 60° C. for time period of 1-4 hours.
- Drugs or bioactives are filled into alginate capsules prepared by method as mentioned in Example 1.
- the capsules were cross-linked with either polymeric blend/s or bi-/trivalent cations in the form of their salt/s and/or combinations thereof to achieve delivery.
- the solubility of the drug changes the rate of release kinetics was altered.
- the cross-linking of cations with alginate showed varied release profiles ranging from immediate to delayed release up to 8 hours ( FIG. 2 ). Therefore, cross-linked alginate capsules are prepared to obtain wide-ranging release profiles, to improve the bioavailability or stability and to target drug to specific sites. This also offers the advantages, like limiting drug fluctuation within therapeutic range, reducing the side effects, and decreasing dose frequency and improving patient compliance.
- Capsules were allowed to dry and filled up with suitable API and subjected to in vitro drug/bio-active dissolution study.
- the characterization of final empty capsules was carried out by measuring the following physical specifications:
- Dissolution profile of the following drug compounds were determined using alginate gel and its capsule and it was crosslinked with calcium chloride ions.
- dissolution profile of H + proton pump inhibitor—Omeprazole as bare API was filled in alginate capsule.
- Omeprazole was protected from contact with acidic gastric acid in stomach until its relevance gastric emptying time for more than 2 hours. This was achieved by designing >03 layered alginate capsules which are cross-linked with cations in the form of their salt such as Ca ++ .
- FIG. 4 shows the dissolution profile of Metformin hydrochloride in alginate capsule.
- 02 layers of alginate capsules were prepared and cross-linked with cations in the form of their salt/s such as Ca ++ .
- the dissolution profile indicated that ⁇ 90% drug release happened within an hour for water-soluble drug was achieved.
- the said pharmaceutical composition is an immediate release dosage form, characterized by its dissolution profile wherein after 30 minutes at least 85% by weight of the active ingredient/s is dissolved.
- FIG. 5 shows the dissolution profile for alginate capsule having Metoprolol tartrate in 0.1M HCl (4 Hrs), pH 6.8 Phosphate buffer (4 Hrs.) and pH 6.8 phosphate buffer (4 Hrs).
- the results indicate that a pulsatile release with chronopharmacological behavior. This was achieved by 03 layers of alginate which was cross-linked with bivalent cations in the form of their salt/s such as Ca ++ .
- the pulsatile release of Metoprolol tartrate with an hour of lag period influence drug release that ideally matches the circadian rhythm (24 hour) of the body in association with a specific disease.
- FIG. 6 shows dissolution profile for alginate capsule having Mesalamine in 0.1M HCl (2 Hrs), pH 6.0 phosphate buffer (1 Hr) and pH 7.2 Phosphate buffer (3 hrs).
- the results indicate colon targeted modified release. This was achieved by 03 layers of alginate cross-linked with bivalent cations in the form of their salt/s such as Ca ++ .
- the delayed release of Mesalamine with 0 ⁇ 3 hour of lag period influence drug to reach preferred sites of delivery-distal gut (ileum and/or colon) without absorption from the small intestine ability at distal sites in the gut and its release in colon that increases the residence time to treat Ulcerative colitis and IBD.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention is related to polymer-based formulation for release of drugs and bioactives at gastrointestinal tract specific sites including stomach, intestine and colon.
Description
- This application is continuation of U.S. Nonprovisional patent application Ser. No. 16/605,652, filed 16 Oct. 2019, which is a National Stage Application of PCT/IB2018/052496, filed 10 Apr. 2018, titled POLYMER BASED FORMULATION FOR RELEASE OF DRUGS AND BIOACTIVES AT SPECIFIC GIT SITES, published as International Patent Application Publication No. WO 2018/193337 A2, which claims the benefit of and priority to Indian Complete Application 201721013710, filed on Apr. 18, 2017, all of which are incorporated by reference herein in their entirety for all purposes.
- The present invention provides desired drug/bio-active release formulation in solid dosage form comprising variable physico-chemical properties of Active Pharmaceutical Ingredients (APIs) and other bio-actives including proteins by means of polymer capsule as a unit dosage form. The above said dosage form comprises natural polymer example, sodium alginate with bi- and/or trivalent ions chemically balanced cations to control the release of drug/bio-actives at specific time and at specific GIT sites.
- Solid dosage forms and such drug delivery systems with oral route, remains the most desired and accepted route of administration. Oral dosage systems are able to release the drug at a constant rate for a given time period with multiple release profile/s are thus of interest. Conventional solid dosage forms consist of active agent and biologically inert auxiliary substances which are the pharmaceutical excipients. Conventional dosage forms release the drug following which drug is very rapidly dissolved and quickly builds up to a maximum high concentration in GIT. The result is an undulating concentration of the drug in the stomach or intestine, thus in the systemic circulation and tissues. The dosage form may thus release high of or low concentrations of drugs which may under-serve the patient's needs. Often, this may cause problems in maintaining therapeutic drug levels over only brief duration of time which may either lead to an insufficient efficacy provoking an excessive drug dumping.
- Therefore, for the successful pharmaco-treatment, an ideal drug delivery system should be (a) able to deliver the drug at a rate to co-relate in vivo bioequivalence, and (b) deliver the drug to its targeted site, for example, as in the case of inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and colonic cancer. The conventional pharmaceutical formulation strategies do not meet these delivery abilities required by specific conditions or diseases.
- Various controlled drug delivery systems (CDDS) have been developed with aspects of time and spatial control of drug release. CDDS are conventionally achieved by following approaches, i) diffusion controlled, ii) degradation or erosion controlled, iii) osmotic controlled and iv) swelling controlled. This results with constant uniform concentration of drug in blood and tissues over a period of time, with the following advantages: (i) reduced amount of drug administered reduces the problems of side effects, improving the safety of therapy, (ii) the patient compliance is achieved with such types of dosage forms, as the frequency of administration is considerably lower.
- In CDDS, the dosage form has uniform packing characteristics over a range of different particle size distributions and is capable of processing into various solid dosage forms viz. tablets, capsules, pellets, enteric coating, etc. Conclusively, rate of drug release is controlled by the rate of water penetration into the dosage form matrix. In order to achieve the desired drug release profile, various rate controlling polymers are added into the dosage form. This increases the process and thus the cost of the therapy. However, the drug dumping is associated especially with such unit dosage forms. Further, various specialized technologies such as, osmotic controlled release formulations require number of processing operations which subsequently increases the processing time. Multiple processing of unit dosage form includes coating with specific polymers, e.g. enteric coating (Time controlled drug delivery systems, In: A. T. Florence, J. Siepmann (Eds.) Modern Pharmaceutics Volume 2: Applications and Advances, Informa Healthcare USA; Inc., New York, N.Y.; 2009; 1-22).
- Newer solid dosage forms are envisioned to achieve the drug and other actives to be released at various GIT sites. However, all solid dosage forms overrides the physiological implications, including the gastric pH, varied gastric retention times and other physiological limitations including the organ emptying time. For example, many drugs (e.g. Omeprazole, esomeprazole, pantoprazole, etc.) are unstable in stomach pH thereby results in drug degradation and hydrolysis, ineffective drug absorption and lowered therapeutic efficacy. This is overcome by process technology now routinely practiced as a ‘pelletization process’ followed by enteric coating using pH sensitive polymers (example, Eudragit).
- While, circadian rhythms are of great significance in therapeutics such in selecting the specific time of drug administration which directly influences its pharmacokinetics, adverse effects, efficacy and overall therapeutic outcome. Chronopharmaceutics provides drug release that ideally matches the circadian rhythm (24 hour) of the body in association with a specific disease, e.g. hypertension (U.S. Pat. No. 6,229,396).
- The chronopharmaceutical technologies based on physical and/or chemical activation for controlled drug release that is intended for different route of administration (Adv Drug Deliv Rev., 2010, 62, 898-903). Several diseases, wherein the symptoms are most intense during nighttime or early morning, for example, cardiovascular diseases, bronchial asthma, duodenal ulcer, osteoarthritis, etc. are shown to follow circadian rhythms. Thus, providing treatment at the required hour would mean a more logical and clinically relevant approach to development of oral pulsatile drug delivery systems. Currently, there are major roadblocks for the successful transition of such system to reach technology to patient. These include the challenges to identify adequate (i) Suitable polymers, (ii) rhythm engineering modeling and their system biology and (iii) regulatory guidance.
- On the other hand, pulsatile drug delivery systems have gained increasing interest during recent years because of its ability to release the drug rapidly and completely after a defined lag time. Pulsatile release profiles are suitable for drugs with (1) higher first-pass metabolism, (2) which develop biological tolerance, (3) which are targeted to a specific site in GIT, such as colon, (4) which need protection from degradation, and to meet the chronotherapeutical diseases. Ambulatory blood pressure has reported to exhibit diurnal pattern with a surge in the early morning time which is considered to be a major factor behind high risk of cardiac death, ischemic and hemorrhagic stroke. Therefore, there is a need of an antihypertensive drug to have higher plasma concentration for morning surge in blood pressure9,10,11.
- Furthermore, various formulation strategies to target the colon include the polymeric coatings of the dosage form to provide the delayed drug release because of the degradation of coating facilitated by presence of either change in pH, pressure, time-dependent polymeric films or microorganism flora.
- Colon targeted drug delivery system need to overcome the hurdles in the form of acidic pH of stomach and slightly alkaline pH in small intestine. They are expected to initiate drug release in large intestine. These systems work on the principle of solubilization of polymer coating at alkaline pH above 7. Polymers such as Eudragit L100 which is soluble above pH 5.5 to 6.5 and Eudragit 5100, soluble above
pH 7 are commonly used. - The wide variety of enzymes, such as glucoronidase, xylosidase, arabinosidase, amylase, pectinase, xylanase, galactomannanase, nitroreductase, azoreductase, deaminase, urea dehydroxylase have been reported to produce micro-biota of colon. Polysaccharides of natural origin obtained from plant, algal, animal or microbial origin such as calcium pectinate, chitosan, chondroitin sulphate, galactomanan, and amylose are mostly used for micro-biota-activated coatings.
- There are few issues from the viewpoint of regulatory bodies associated with azo-compounds such as firstly, the need for an organic solvent for their solubilization and secondly non-established safety profile. In general, to achieve drug delivery to colon typically comprises solid dosage forms coated with pH resistant polymers. Colon targeting is achieved by using biodegradable polymers such as cellulose acetate pthalate and shellac. On the other hand, enteric coating is achieved by using various acrylic polymers.
- Pressure-dependent devices are meant to be ruptured because of the relatively elevated pressure in large intestine compared to small intestine due to peristaltic movement. Finally, time-dependent coatings releases the pay load in colon as a consequence of either of the following mechanisms, which are, timed erosion, disintegration or enhanced permeability irrespective of above mentioned physiological variables. It has been hypothesized that, there is a marked decrease in the pH of proximal large intestine of IBD patients. This could be the cause in few of the instances, that coating of Eudragit S100 has failed to dissolve as intact tablet. On the other hand, as revealed by scintigraphic evaluation, tablets coated with Eudragit L100, were found to dissolve in the distal small intestine (Eur. J. Pharm. Sci., 2013, 49, 712-722; Int. J. Pharm, 2013, 457, 372-395).
- U.S. Pat. No. 6,228,396 discloses a colonic drug delivery composition comprising a starch capsule containing drug. Colon targeting is achieved by means of a coating comprising of a pH sensitive material, a redox sensitive material or a material which could be broken down by the enzymes or microbiota present in the colon. Capsule formulations containing API mesalamine for colon targeting is available in market (e.g. Delzicol, Apriso, Pentasa). Similarly, tablet formulations coated with a pH dependent coating which dissolves above
pH 7 are also available in market (e.g. Asacol HD, Lialda). - Commercially, there are various solid dosage forms with widespread therapeutics for oral administration, for example, Delzicol™, Apriso™, Pentasa™. U.S. Pat. No. 5,482,718 and U.S. Pat. No. 6,039,975 disclose colon-targeted delivery system wherein the core is comprised of a drug and a carrier and the said core is coated with an erodible polymer layer with/without Eudragit®. The use of pH-dependent polymers in combination with acidic/amphoteric drugs such as measalamine bears several difficulties. The desired drug delivery profile from modified release formulations containing ionisable drugs and/or ionic polymers such as enteric coating can be affected by pH and composition on intestinal fluids (Journal of Pharmacy and Pharmacology; 2014; 1-10). U.S. Pat. Nos. 5,171,580, 5,603,9975, WO2011045775, WO 2005030173 and U.S. Pat. No. 4,871,549 disclose coated drugs maximizing the use of excipients in the formulation leading to increase in the number of manufacturing processes.
- In general, in order to achieve CDDS, the technologies involve tableting process and the use of coating of solid dosage forms with different polymers. Essentially, the pharmaceutical process involves multi-steps and use of multiple excipients. And yet the ‘tunability’ to achieve the control over the drug release profiles is questionable with often drug dumping and lower patient compliance.
- In the present invention, Applicants propose a non-tableting, non-coating platform (capsule as a solid dosage form) using natural polymer/s to control the release of drug/bioactives at specific time and at various specific GIT sites. The rate of release of actives is achieved as immediate-, extended-, sustained, lag-, pulsatile-, or delayed-drug release profiles (e.g. site—colon delivery). Herein, capsules as a dosage form comprising sodium alginate with bi- and/or trivalent chemically balanced ions to control the release of drug/bio-actives at specific time and at specific GIT sites are demonstrated.
- The present invention provides solid dosage formulation in the form of capsule to achieve multiple drug dissolution profiles. The dosage form protects degradation of the drug in gastric environment (APIs e.g. Omeprazole, esomeprazole, pantoprazole and all grouped azoles), or achieve controlled/extended release of drug/bio-actives, and attain lag or pulse release profile (e.g. Metoprolol, Amlodipine, etc.). The dosage form also achieves the delayed release in small or large intestine or at colon site (e.g. Mesalamine, budesonide, infliximab, peptides, proteins or other bioactives etc.). The preparation of such solid dosage formulation is also provided. The invention also encompasses that such modified drug dissolution platform is useful to supplement the nutraceuticals or dietary minerals with divalent cations (e.g. Na+, Mg++, Ca++).
- The present invention relates to a drug delivery formulation in the form of polymer capsules for delivering different drugs and bioactives at various GIT sites, inclduing stomach, intestine and colon having varied drug release profiles.
- The capsule of the present invention achieves the delayed release of the anti-inflammatory or anticacner drugs, e.g. mesalamine, 5-flurouracil, etc. for colon delivery.
- The formulation composition reported in the present invention does not involve application of coating step by using any of the available enteric or biodegradable polymers nor any other excipient.
- The present invention comprises the dosage form using polymer of natural origin, sodium alginate which is resistant to acidic pH. The thickness and toughness of the polymer/s is so adjusted that, it remains intact during its transit through stomach and intestine. Once the capsule reaches colon, it will achieve the burst release of the drug because of the swelling of polymer at higher pH values and also by subsequent rapid erosion. The release profiles achieved are highly essential in treating Crohn's disease, colon cancer, Irritable Bowl Syndrome (IBS) and other GI-related disorders.
- One aspect of the invention is to design the capsules using alginate crossed linked with multi-cations in the form of Form-Fill-Seal (FFS) process for site-specific delivery as colon targeting.
-
FIG. 1 . Schematic for preparation of capsule dosage form comprising polymer and ions and the Dimensions of drug releasing polymer capsule using multi ions of alginate gel. -
FIG. 2 . Varied release profiles of APIs with alginate and/or bi- or trivalent ions and/or polymers. -
FIG. 3 . Dissolution profile of H+ proton pump inhibitor Omeprazole—a pH unstable API. -
FIG. 4 . Dissolution profile of Metformin Hydrochloride showing Immediate Release (IR) Profile. -
FIG. 5 . Dissolution profile of Metoprolol tartrate in 0.1M HCl (4 Hrs), pH 6.8 Phosphate buffer (4 Hrs) and pH 7.6 Phosphate buffer (4 Hrs). -
FIG. 6 . Dissolution profile of Mesalamine in 0.1M HCl (2 Hrs), pH 6.0 Phosphate buffer (1 Hr) and pH 7.2 Phosphate buffer (3 Hrs). - The present invention is related to a polymer-based formulation for release of drugs and bio-actives at GIT specific sites. In one embodiment, the invention describes a dosage form comprising sodium alginate with bi- and/or trivalent chemically balanced cations to control the release of drug/bio-actives at specific time and at specific GIT sites. Herein, the applicant details a modified drug releasing pharmaceutical formulation as a capsule dosage form comprising Form-Fill-Seal (FFS) capsule processing. This brings ease of administration, subsequently avoiding inconvenient route of administration for dosage forms like suppositories and enemas. Avoidance of systemic absorption of drugs and consequently its unwanted distribution to tissues in the body is also achieved. This is applicable for site specific drug targeting for efficient local treatment of large bowel diseases, such as inflammatory bowel disease, ulcerative colitis, amebiasis, and colonic cancer. The polymeric capsule can deliver drugs or proteins and peptide drugs. Rectal administration is also limited by availability of lesser number of dosage forms (solutions, foams, enemas, and suppositories) and drug also remains localized to rectum and distal colon if administered by this route.
- In another embodiment, the invention describes the preparation of said formulation and its release profile for wide-ranging therapeutics as a “capsule” prepared by finely tuned composition of bi- and/or trivalent cations and natural and/or synthetic polymer/s or combination thereof to control the release of drug/bioactives at specific time and at specific GIT sites.
- The term “modified release” includes, but is not limited to, immediate-, extended-, sustained-, lag- and pulsatile-, or delayed-, or combination of drug release profiles in pharmaceutical formulation.
- The present invention demonstrates a novel composition that offers greater multiplicity and flexibility in the release profile to be obtained with finely tuned natural polymer, sodium alginate using di- and/or tri-valent cations and natural/semi-synthetic/synthetic polymer.
- The relative ionic affinity and ability to form gels has been extensively studied for natural polymer, sodium alginate and a range of divalent cations is established the following series for the concentration of divalent cations required to bring about gelation of alginate: Ba<Pb<Cu<Sr<Cd<Ca<Zn<Ni<Co<Mn, Fe<Mg.
- The mechanical properties of alginate gels are dependent mainly upon and affinity towards bi-valent or trivalent cations which bring about (a) stiffness of the individual polymer chains in alginate and (b) the nature and the strength of the forces whereby bi- or trivalent metal ions bind different chains together. Thus, alginate gels are crosslinked with bi- or trivalent cations.
- In the present invention, the release rate profiles of bioactives is achieved when the alginate concentration was varied from 1% to 6% w/v ionic concentrations. For example, when alginate concentration was higher than 2%, it promoted the saturation for ionic binding. Also, addition of Fe+++ promoted faster diffusion of Ca++ and reduced Ca++ equilibrium concentration. Also, Fe+++ ions entrapped in the alginate capsule promoted greater absorption of water compared to pure alginate gel.
- Further, by addition of Mg++ ions, the alginate achieves lower gelation almost 4 times than the equivalent amount of CaCl2 and/or FeCl3.
- The formulation of the present invention allows the release of drug/bioactive to reach at specific time and at specific site/s in a controlled manner e. g. extended-, sustained-, lag-, pulsatile-, or delayed-drug release profiles. The formulation is modulated by process of forming capsule shell to achieve desired release profile/s. Herein, the type and content of natural polymer blended and/or cross-linked with bi- and/or trivalent ions in the form of their salts with one or many natural or synthetic excipients/polymers to reach appropriate thickness of the layer on substrate was considered.
- It is observed that for oral administration of controlled-, sustained-, pulsatile-, extended- or delayed-release pharmaceutical compositions comprising bare API (No API processing), capsule shell composition provide a high unit dose of the active ingredient; exhibit desired in-vitro release profiles and in-vivo performance. Moreover, the formulation of the invention presents the advantage that it is cost effective since one polymer with bare API is needed to control the release of the active ingredient, thus facilitating relatively cheaper manufacturing process. In addition to optimum dissolution profile, the formulation of the invention presents an advantage of compatibility between natural polymer and drug/bioactive with better stability on storage.
- Capsule shell composition comprises sodium alginate, bi- and/or trivalent cations in the form of their salts, for example: CaCl2, FeCl3, BaCl2, MgCl2, and MnCl2 and/or polymers, for example: CMC, HPMC, HPC, starch, cross-linked sodium CMC/HPC; high-molecular weight polyvinylalcohols; gums such as natural gum, psyllium husk, tamarind gum, agar, agarose, sodium alginate, carrageenan, gum arabic, gum ghatti, gum karaya, gum tragacanth and xanthan gum; hydrophilic colloids such as alginates, carbopol and polyacrylamides; other substances such as arbinogalactan, pectin, amylopectin, gelatin, and N-vinyl lactams; polysaccharides; chitosan, hyaluronic acid and the like. Combinations of any two or more of these cations, and/or polymers having the required properties to achieve specific drug release profiles are within the scope of the invention.
- The dosage form of the present invention is a capsule comprising (a) drug/bioactives including peptide, proteins, natural/mineral oils, enzymes, vitamins and mixtures thereof; (b) polymer sodium alginate blended with natural or synthetic polymers. The polymer blends that can be used with cross-linked alginate includes but not limited to HPMC, CMC, PVA, gelatin, starch and so on.
- In one embodiment, the present invention comprises pharmaceutical composition of capsule shell comprising:
-
- (a) 0.01 to 6% w/v aqueous solution of Sodium alginate.
- (b) 0.025 to 18% w/v of bi- and/or trivalent ions in the form of their salts,
- (c) 0.01 to 10% w/v natural and/or semi-synthetic and/or synthetic polymer/s.
- In another embodiment, the pharmaceutical composition of the present invention comprise a therapeutically effective quantity of drug/bioactive or its pharmaceutically acceptable salts. The said composition is in a solid unit dosage form, as a capsule, made up of a single polymer of natural origin, which can be tuned to achieve various drug release profiles, such as, immediate (e. g. metformin capsule,
FIG. 4 ), pulsatile (e.g. metoprolol hydrochloride capsule,FIG. 5 ) and colon targeted or delayed release (e. g. mesalamine capsule,FIG. 6 ). - The pharmaceutical composition of the present invention provides protection from acidic environment in the stomach for proton pump inhibitor drugs without the need to apply enteric coating; these drugs include but not limited to Omeprazole, Rabeprazole, Pantoprazole and so on, which act by immediate drug release as soon as the dosage form reaches proximal part of small intestine. Thus the pharmaceutical composition of the present invention can deliver site specific drug release to colon for various APIs (e. g. mesalamine, budesonide, infliximab, etc.) as well as proteins and peptides, etc.
- The pharmaceutical composition of the present invention can also be prepared using any of the substrates such as stainless-steel capsule pins, glass rods, teflon rods and brass capsule pins.
- It is envisaged that the pharmaceutical composition of the present invention which is a capsule formulation can be altered by achieving suitable thickness and toughness so as to deliver drug to the colonic region. The required thickness and toughness of the composition is achieved by increasing the number of capsule layers which may vary from one to eight. Thus the drug release can be modified or defined by the number of layers of the substrate. As the number of alginate layers increases, the release rate of bioactive from the capsule decreases.
- Furthermore, the pharmaceutical composition of the invention is delivered via systemic route when the drug/bioactive is a protein or a peptide.
- The pharmaceutical composition of the invention is useful for delivering the drug/bioactive at specific site and specific time in conditions such as IBD and cancer. Thus, the bioactive release rate can be tuned by changing the number of layers of capsules.
- Due to high ionic crosslinked system and H+ resistant alginate polymer capsule, the rate of hydration in stomach until its emptying time will be negligible. This will preserve the release of bioactive. Further, due to high ions the capsule will have lower hydration in intestinal buffers. The capsule at intestinal pH and due to long retention time there will initiate hydration resulting in swelling. While, it reaches to colon, the swelled capsule is expected to release the bioactive in colon pH. This can be tuned based on number of alginate layers and crosslinking ratio's of ions.
- Furthermore, the formulation of the invention delivers the bioactives by oral route when the drug/bioactive is protein or a peptide. It is expected that the capsule will protect these bioactives from early release in stomach and intestine. The rate of release will be delayed when the capsule reaches colon.
- The pharmaceutical composition of the present invention describes the dosage form comprising sodium alginate crosslinked with bi- and/or trivalent ions to control the release of drug/bio-actives at specific time and at specific GIT sites.
- Suitable grade of alginate polymer was selected and a gel was prepared in distilled water in concentration ranging from 0.1-6% w/v. A substrate (e.g. stainless-steel capsule pins, glass rods, teflon rods and brass capsule pins), was dipped into the alginate polymer gel for a time period of 10-60 seconds and removed. In the next stage, the substrate on which polymer gel was coated was dipped into aqueous solution of di- or trivalent ions or their mixtures (example, CaCl2, FeCl3 and MgCl2 having concentration from 0.025 to 12% w/v) thereof in the form of their salts and/or polymer having concentration from 0.05 to 6% w/v and 0.01 to 6% w/v respectively for a time period between 30 seconds to 1 hour (
FIG. 1 ). This process allows cross-linking which leads to solidification of alginate. The substrate was then removed and dried in hot air oven at any temperature between 40° C. to 60° C. for time period of 1-4 hours. - To get suitable thickness, layer by layer depositions from 1 to 8 layers of the polymer was achieved by repeating the same steps mentioned above (
FIG. 1 ). Suitable thicknesses of the capsules allow generating different drug release profiles. Later on, the substrates containing dried polymer layers were again dipped into same concentration of salt/s as used in the initial stage of polymer cross-linking, which allows complete hydration and formed capsules were then removed with ease from the substrate. - Drugs or bioactives are filled into alginate capsules prepared by method as mentioned in Example 1. The capsules were cross-linked with either polymeric blend/s or bi-/trivalent cations in the form of their salt/s and/or combinations thereof to achieve delivery. As the solubility of the drug changes the rate of release kinetics was altered. The cross-linking of cations with alginate showed varied release profiles ranging from immediate to delayed release up to 8 hours (
FIG. 2 ). Therefore, cross-linked alginate capsules are prepared to obtain wide-ranging release profiles, to improve the bioavailability or stability and to target drug to specific sites. This also offers the advantages, like limiting drug fluctuation within therapeutic range, reducing the side effects, and decreasing dose frequency and improving patient compliance. - Capsules were allowed to dry and filled up with suitable API and subjected to in vitro drug/bio-active dissolution study. The characterization of final empty capsules was carried out by measuring the following physical specifications:
-
- Empty Capsule weight (mg)
- Empty Capsule weight of cap and body (mg)
- Empty Capsule- body volume capacity (ml)
- Empty Capsule weight capacity by formulation density (mg)
- Empty Capsule length (mm)
- Empty Capsule individual length/s of cap and body (mm)
- Empty Capsule external and internal diameter cap and body (mm)
-
-
Physical characterization of final empty capsules Entry Parameter Size Range 1. Empty Capsule weight (mg) 170-180 2. Empty Capsule weight of cap (mg) And 66-72 Empty Capsule weight of body (mg) 102-112 3. Empty Capsule-body volume capacity (ml) 0.65-7 4. Empty Capsule weight capacity by formulation 250-350 density (mg) 5. Empty Capsule length (mm) 21.2-22.2 6. Empty Capsule individual length of cap (mm) 10.5-11.5 Empty Capsule individual length of body (mm) 18.2-19.2 7. Empty Capsule external diameter of cap (mm) 7.4-7.8 Empty Capsule internal diameter of cap (mm) 7.2-7.6 Empty Capsule external diameter body (mm) 7.0-7.2 Empty Capsule internal diameter body (mm) 6.8-7.0 - Dissolution profile of the following drug compounds were determined using alginate gel and its capsule and it was crosslinked with calcium chloride ions.
- In
FIG. 3 , dissolution profile of H+ proton pump inhibitor—Omeprazole as bare API was filled in alginate capsule. Omeprazole was protected from contact with acidic gastric acid in stomach until its relevance gastric emptying time for more than 2 hours. This was achieved by designing >03 layered alginate capsules which are cross-linked with cations in the form of their salt such as Ca++. -
FIG. 4 shows the dissolution profile of Metformin hydrochloride in alginate capsule. 02 layers of alginate capsules were prepared and cross-linked with cations in the form of their salt/s such as Ca++. The dissolution profile indicated that ≥90% drug release happened within an hour for water-soluble drug was achieved. The said pharmaceutical composition is an immediate release dosage form, characterized by its dissolution profile wherein after 30 minutes at least 85% by weight of the active ingredient/s is dissolved. -
FIG. 5 shows the dissolution profile for alginate capsule having Metoprolol tartrate in 0.1M HCl (4 Hrs), pH 6.8 Phosphate buffer (4 Hrs.) and pH 6.8 phosphate buffer (4 Hrs). The results indicate that a pulsatile release with chronopharmacological behavior. This was achieved by 03 layers of alginate which was cross-linked with bivalent cations in the form of their salt/s such as Ca++. The pulsatile release of Metoprolol tartrate with an hour of lag period influence drug release that ideally matches the circadian rhythm (24 hour) of the body in association with a specific disease. -
FIG. 6 shows dissolution profile for alginate capsule having Mesalamine in 0.1M HCl (2 Hrs), pH 6.0 phosphate buffer (1 Hr) and pH 7.2 Phosphate buffer (3 hrs). The results indicate colon targeted modified release. This was achieved by 03 layers of alginate cross-linked with bivalent cations in the form of their salt/s such as Ca++. The delayed release of Mesalamine with 0≥3 hour of lag period influence drug to reach preferred sites of delivery-distal gut (ileum and/or colon) without absorption from the small intestine ability at distal sites in the gut and its release in colon that increases the residence time to treat Ulcerative colitis and IBD. - With altering the number of the alginate capsule, modified-profiles releases were achieved from immediate-release viz. metformin hydrochloride to a drug with a delay after its administration (delayed-release dosage) or for a prolonged period of time (extended-release [ER, XR, XL] dosage) or to a specific GIT target viz. colon (targeted-release dosage).
Claims (12)
1. A pharmaceutical composition in a solid oral unit dosage form comprising:
a drug or bioactive; and
a sodium alginate polymer chemically crosslinked with bivalent ions, trivalent ions, or a combination thereof, for controlling the release of the drug or bioactive at specific time and at specific sites.
2. A pharmaceutical composition in a solid oral unit dosage form comprising:
a drug or bioactive; and
a sodium alginate polymer chemically crosslinked with bivalent ions, trivalent ions, or a combination thereof for controlling the release of the drug or bioactive at specific time and at specific sites,
wherein the said pharmaceutical composition is free from tableting process of granulation or coating.
3. The pharmaceutical composition of claim 1 , wherein the said specific site is gastrointestinal (GIT) site.
4. The pharmaceutical composition of claim 1 , comprising a capsule formulation selected from the group consisting of capsules, tablets in capsules, bilayer tablet, single-layered capsule, or multi-layered capsule.
5. The pharmaceutical composition of claim 4 , wherein the capsule formulation is delivered as immediate drug release, extended-drug release, sustained-drug release, lag-drug release, pulsatile-drug release, delayed-drug release, modified drug release (MDR), or any combinations of profiles at specific time and site.
6. The pharmaceutical composition of claim 4 , wherein the capsule formulation is selected from the group consisting of powder, pellets, enteric-coated granules, and tablets.
7. The pharmaceutical composition of claim 1 , wherein the said drug is selected from a group consisting of water-soluble, water-insoluble, acid-labile, non-acid labile, proteins and peptides.
8. The pharmaceutical composition of claim 4 , wherein the said capsule comprises a shell made of blended natural polymer, blended synthetic polymer, cross-linked natural polymer, cross-linked synthetic polymer, or a combination thereof.
9. The pharmaceutical composition of claim 4 , wherein the said capsule formulation comprises capsule shell comprising 0.1-6% w/v aqueous solution of sodium alginate, 0.05 to 18% w/v of bivalent ions, trivalent ions, or a combination thereof, in the form of their salts and 0.01 to 10% w/v of polymers.
10. The pharmaceutical composition of claim 9 , wherein the said polymer is cross-linked with bi- and/or trivalent ions in the form of their salts and or blended with natural or semi-synthetic or synthetic polymer or their combination.
11. The pharmaceutical composition of claim 4 , wherein the said capsule is tough and thick and wherein the said strength and toughness is achieved by increasing the number of capsule layers.
12. A method of treating irritable bowel disease or cancer, the method comprising administering a pharmaceutical composition in a solid oral unit dosage form comprising:
a drug or bioactive; and
a sodium alginate polymer chemically crosslinked with bivalent ions, trivalent ions, or a combination thereof for controlling the release of the drug or bioactive at specific time and at specific sites,
wherein the drug or bioactive is delivered in colon and is effective for the treatment of irritable disease or cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/164,174 US20230181479A1 (en) | 2017-04-18 | 2023-02-03 | Polymer based formulation for release of drugs and bioactives at specific git sites |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721013710 | 2017-04-18 | ||
IN201721013710 | 2017-04-18 | ||
PCT/IB2018/052496 WO2018193337A2 (en) | 2017-04-18 | 2018-04-10 | Polymer based formulation for release of drugs and bioactives at specific git sites |
US201916605652A | 2019-10-16 | 2019-10-16 | |
US18/164,174 US20230181479A1 (en) | 2017-04-18 | 2023-02-03 | Polymer based formulation for release of drugs and bioactives at specific git sites |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/605,652 Continuation US11596607B2 (en) | 2017-04-18 | 2018-04-10 | Polymer based formulation for release of drugs and bioactives at specific GIT sites |
PCT/IB2018/052496 Continuation WO2018193337A2 (en) | 2017-04-18 | 2018-04-10 | Polymer based formulation for release of drugs and bioactives at specific git sites |
Publications (1)
Publication Number | Publication Date |
---|---|
US20230181479A1 true US20230181479A1 (en) | 2023-06-15 |
Family
ID=63855631
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/605,652 Active US11596607B2 (en) | 2017-04-18 | 2018-04-10 | Polymer based formulation for release of drugs and bioactives at specific GIT sites |
US18/164,174 Abandoned US20230181479A1 (en) | 2017-04-18 | 2023-02-03 | Polymer based formulation for release of drugs and bioactives at specific git sites |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/605,652 Active US11596607B2 (en) | 2017-04-18 | 2018-04-10 | Polymer based formulation for release of drugs and bioactives at specific GIT sites |
Country Status (4)
Country | Link |
---|---|
US (2) | US11596607B2 (en) |
EP (1) | EP3612196A4 (en) |
CA (1) | CA3060026A1 (en) |
WO (1) | WO2018193337A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3060026A1 (en) * | 2017-04-18 | 2018-10-25 | Jayant Jagannath Khandare | Polymer based formulation for release of drugs and bioactives at specific git sites |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4738817A (en) * | 1983-11-17 | 1988-04-19 | Warner-Lambert Company | Method for forming pharmaceutical capsules from hydrophilic polymers |
GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
IT1230576B (en) | 1988-10-20 | 1991-10-28 | Angeli Inst Spa | ORAL PHARMACEUTICAL FORMULATIONS WITH SELECTIVE LIBERATION IN THE COLON |
US5451411A (en) * | 1993-10-15 | 1995-09-19 | University Of Washington | Methods and compositions for the oral delivery of therapeutic agents |
US5482718A (en) | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
GB9412394D0 (en) | 1994-06-21 | 1994-08-10 | Danbiosyst Uk | Colonic drug delivery composition |
US6039975A (en) | 1995-10-17 | 2000-03-21 | Hoffman-La Roche Inc. | Colon targeted delivery system |
WO2005030173A1 (en) | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Colon-specific drug delivery using interpolymer complexations |
US9884024B2 (en) * | 2005-12-27 | 2018-02-06 | Hemant N Joshi | Physically dispersed, molecularly dissolved and/or chemically bound drug(s) in an empty, hard capsule shell composition |
WO2010064100A1 (en) * | 2008-12-04 | 2010-06-10 | Intec Pharma Ltd. | Baclofen gastroretentive drug delivery system |
WO2011045775A1 (en) | 2009-10-16 | 2011-04-21 | Ranbaxy Laboratories Limited | A delayed release pharmaceutical composition of mesalamine |
US9283147B2 (en) * | 2011-09-28 | 2016-03-15 | Seiko Epson Corporation | Encapsulation device, medical capsules, and encapsulation method |
EP2793867B1 (en) * | 2011-12-22 | 2021-01-20 | Baes, Erik | Gelatin/alginate delayed release capsules comprising omega-3 fatty acids, and methods and uses thereof |
CN103877587B (en) * | 2014-04-11 | 2016-01-20 | 江苏省海洋资源开发研究院(连云港) | Medicinal enteric hard-shell capsule of a kind of vegetable polysaccharides and preparation method thereof |
WO2017027778A1 (en) | 2015-08-13 | 2017-02-16 | Temple University-Of The Commonwealth System Of Higher Education | Calcium alginate dosage formulations, and methods of making and using thereof |
CA3060026A1 (en) | 2017-04-18 | 2018-10-25 | Jayant Jagannath Khandare | Polymer based formulation for release of drugs and bioactives at specific git sites |
-
2018
- 2018-04-10 CA CA3060026A patent/CA3060026A1/en active Pending
- 2018-04-10 WO PCT/IB2018/052496 patent/WO2018193337A2/en unknown
- 2018-04-10 EP EP18787616.4A patent/EP3612196A4/en active Pending
- 2018-04-10 US US16/605,652 patent/US11596607B2/en active Active
-
2023
- 2023-02-03 US US18/164,174 patent/US20230181479A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3612196A2 (en) | 2020-02-26 |
US20200129442A1 (en) | 2020-04-30 |
US11596607B2 (en) | 2023-03-07 |
WO2018193337A3 (en) | 2019-02-07 |
EP3612196A4 (en) | 2021-01-13 |
CA3060026A1 (en) | 2018-10-25 |
WO2018193337A2 (en) | 2018-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6881420B2 (en) | Compositions and dosage forms for gastric delivery of irinotecan and methods of treatment that use it to inhibit cancer cell proliferation | |
EP1916995B2 (en) | Ph-controlled pulsatile delivery system, methods for preparation and use thereof | |
WO2014174073A1 (en) | Sustained release formulations of tofacitinib | |
PT97370B (en) | PROCESS FOR THE PREPARATION OF A CONTROLLED LIBERATION FORMULA IN THE FORM OF A PLURALITY OF MULTIDOSE UNITS | |
JPH09503782A (en) | Picosulfate dosage form | |
TW201742621A (en) | Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating | |
US20230181479A1 (en) | Polymer based formulation for release of drugs and bioactives at specific git sites | |
WO2007113207A2 (en) | Coated formulations | |
Scholtz et al. | More good news about polymeric plant-and algae-derived biomaterials in drug delivery systems | |
JP4771956B2 (en) | Composition of a quaternary ammonium compound containing a bioavailability enhancer | |
JP7499232B2 (en) | Controlled release drug dosage forms | |
AU732210B2 (en) | Colonic delivery of weak acid drugs | |
RU2440104C2 (en) | Coating composition containing starch | |
KR20130121717A (en) | Sustained release preparation using gastric retentive drug delivery system | |
JP7423629B2 (en) | Colonic drug delivery formulation | |
Iglesias Blanco et al. | In-Depth Study into Polymeric Materials in Low-Density Gastroretentive Formulations | |
JP6454630B2 (en) | pH-controlled pulse delivery system, preparation and use thereof | |
KR100212432B1 (en) | Composition for colonic drug delivery | |
CA3160869A1 (en) | Dosage form for use in treating or preventing of a disease | |
Naiserová et al. | perorálních tablet | |
BR112020008756A2 (en) | oral pharmaceutical compositions of lorazepam resistant to alcohol | |
JP2017203031A (en) | Ph-controlled pulsatile delivery system, methods for preparation and use thereof | |
Wilson et al. | Programmed drug delivery systems and the colon | |
JP2005075830A (en) | Universal release control composition | |
JP2014139210A (en) | pH-CONTROLLED PULSATILE DELIVERY SYSTEM, METHOD FOR PREPARATION AND USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ACTORIOUS INNOVATIONS AND RESEARCH PVT. LTD., INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KHANDARE, JAYANT JAGANNATH;GOTHOSKAR, ABHIJIT;KULKARNI, NILESH;AND OTHERS;SIGNING DATES FROM 20191002 TO 20191003;REEL/FRAME:062605/0820 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |